SG Americas Securities LLC Buys 59,071 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

SG Americas Securities LLC increased its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 185.5% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 90,921 shares of the biopharmaceutical company’s stock after purchasing an additional 59,071 shares during the period. SG Americas Securities LLC owned approximately 0.07% of Alnylam Pharmaceuticals worth $36,155,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Root Financial Partners LLC bought a new stake in Alnylam Pharmaceuticals in the 3rd quarter worth approximately $25,000. Salomon & Ludwin LLC bought a new position in shares of Alnylam Pharmaceuticals during the 3rd quarter valued at $27,000. Caitong International Asset Management Co. Ltd purchased a new position in shares of Alnylam Pharmaceuticals in the 3rd quarter worth $29,000. Ameriflex Group Inc. purchased a new position in shares of Alnylam Pharmaceuticals in the 3rd quarter worth $32,000. Finally, Aster Capital Management DIFC Ltd bought a new stake in shares of Alnylam Pharmaceuticals in the third quarter worth $36,000. Institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Price Performance

NASDAQ ALNY opened at $328.70 on Thursday. The business’s fifty day moving average is $332.13 and its 200 day moving average is $402.21. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $205.87 and a fifty-two week high of $495.55. The company has a debt-to-equity ratio of 1.28, a quick ratio of 2.71 and a current ratio of 2.76. The company has a market capitalization of $43.59 billion, a PE ratio of 192.22 and a beta of 0.36.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, February 12th. The biopharmaceutical company reported $1.25 EPS for the quarter, missing analysts’ consensus estimates of $1.43 by ($0.18). Alnylam Pharmaceuticals had a return on equity of 69.02% and a net margin of 6.43%.The company had revenue of $1.10 billion during the quarter, compared to analysts’ expectations of $1.16 billion. During the same quarter in the previous year, the company earned ($0.65) EPS. The business’s quarterly revenue was up 84.9% compared to the same quarter last year. Sell-side analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Insider Buying and Selling

In other Alnylam Pharmaceuticals news, EVP Tolga Tanguler sold 1,598 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $327.65, for a total transaction of $523,584.70. Following the transaction, the executive vice president owned 36,606 shares of the company’s stock, valued at $11,993,955.90. The trade was a 4.18% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Jeffrey V. Poulton sold 2,206 shares of the company’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $327.65, for a total transaction of $722,795.90. Following the completion of the transaction, the executive vice president owned 64,273 shares of the company’s stock, valued at approximately $21,059,048.45. The trade was a 3.32% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 53,923 shares of company stock worth $18,072,087 in the last ninety days. Corporate insiders own 1.50% of the company’s stock.

Trending Headlines about Alnylam Pharmaceuticals

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright reaffirmed a Buy rating and set a $510 price target, signaling sizable upside vs. the current share price. Article Title
• Positive Sentiment: Needham’s Joseph Stringer maintained a Buy rating and a $510 target, citing underpenetrated TTR market opportunity and commercial momentum. Article Title
• Positive Sentiment: Bank of America reiterated a Buy stance, highlighting durable ATTR growth and Amvuttra commercial momentum as upside drivers. Article Title
• Positive Sentiment: Chardan Capital reaffirmed a Buy rating with a $425 price target, reinforcing upside expectations from sell‑side analysts. Article Title
• Positive Sentiment: Alnylam announced a strategic collaboration with Viz.ai and support for the American Heart Association to advance earlier identification and care coordination for ATTR‑CM — a potential tailwind for market penetration and patient flow into Alnylam’s TTR treatments. Article Title
• Neutral Sentiment: A recent company transcript reviews strategy and progress in transforming ATTR care (useful for qualitative context but no new financials). Article Title
• Neutral Sentiment: Multiple news items report a rise in short‑interest figures but the publicly posted values show zeros/NaN and appear inconsistent — the data currently looks unreliable and likely isn’t driving the move. (Various short‑interest reporting entries)
• Negative Sentiment: On Feb. 12 Alnylam missed the quarter’s EPS estimate ($1.25 vs. $1.43) and posted revenue below consensus ($1.10B vs. $1.16B), a reminder that execution and near‑term results can still disappoint despite bullish sentiment; this remains a downside risk if future quarters miss expectations.

Analyst Ratings Changes

ALNY has been the subject of a number of research reports. Wall Street Zen cut Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, March 21st. Stifel Nicolaus boosted their price target on Alnylam Pharmaceuticals from $495.00 to $508.00 and gave the company a “buy” rating in a research note on Thursday, December 11th. Chardan Capital reaffirmed a “buy” rating and set a $425.00 price target on shares of Alnylam Pharmaceuticals in a research report on Wednesday. Weiss Ratings upgraded shares of Alnylam Pharmaceuticals from a “sell (d-)” rating to a “hold (c-)” rating in a research note on Thursday, January 15th. Finally, Wells Fargo & Company dropped their price objective on shares of Alnylam Pharmaceuticals from $479.00 to $376.00 and set an “equal weight” rating on the stock in a report on Tuesday, January 20th. One analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $468.84.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.